Toronto (ots/PRNewswire) –
- Following the successful launch in Germany of Khiron 1/14, a medicinal cannabis flower with a high CBD content, it is expected to be available to patients in the UK in Q2 / 21
- Khiron plans to introduce more cannabinoid-based products based on its registered strains that were recently exported to Europe from Colombia
- Improvements in the supply chain will increase the availability of cannabinoid-based medicine to patients in the UK
Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a leading vertically integrated cannabis company with core businesses in Latin America and Europe, is pleased to announce an operational update regarding the supply of to give medical cannabis products to Great Britain in accordance with EU-GMP. To avoid bottlenecks and delivery failures, the company has built an offshore inventory of dried cannabis flowers to supply patients in the UK.
In addition, the company is expanding its product portfolio with the launch of the high-CBD flower Khiron 1/14 in the UK in Q2 / 21. This follows a successful launch in Germany, where it is prescribed for indications such as anxiety, substance use disorders, and migraines. Khiron 1/14 will complement the high-THC flower Khiron 20/1, which is already being prescribed to patients in the UK. The company’s EU-GMP-certified partner enables prescribing doctors to also prescribe smaller quantities of the flower products in 5-gram doses (see picture below).
Tejinder Virk, President of Khiron Europe, commented: “The European market is growing continuously and Khiron is optimally positioned with its established training platform for prescribers, growing clinical evidence and our portfolio of EU GMP certified, prescription-ready products. Our team continues to work intensively We are committed to improving patient access to cannabinoid-based medicine, and patients will now benefit from the greater variety and availability of products. In the coming months, we plan to introduce more cannabis-based medicinal products based on our registered Colombian strains. This will allow us to make the data collected from our Colombian clinics available to medical professionals in the UK. “
About Khiron Life Sciences Corp.
Khiron is a vertically integrated medical and CPG cannabis company with core businesses in Latin America and operations in Europe and North America. Khiron is the leading supplier of medical cannabis in Colombia and the first company to be licensed in Colombia to cultivate, produce, nationally distribute, sell and export medical cannabis products with low and high THC content. The company is responsible for displaying medical cannabis prescriptions in Colombia, Peru, Germany and the UK and is ready to start sales in Mexico and Brazil in 2021.
Using its own medical clinics and telemedicine platforms, Khiron combines a patient-centric approach, physician training programs, scientific expertise, product innovation and agricultural infrastructure to drive prescriptions and brand loyalty. The company’s wellbeing unit launched KUIDA, the first CBD skin care brand in Colombia, the
is now marketed in several countries in Latin America, the USA and Great Britain. The company is led by Co-Founder and Chief Executive Officer, Alvaro Torres, along with an experienced and diverse executive team and the Board of Directors.
More information on www.khiron.ca
This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities laws. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron has no obligation to comment on any analysis, expectations, or statements by any third party with respect to Khiron, its securities, or financial or operating results (as applicable). While Khiron believes that the expectations reflected in the forward-looking statements in this press release are reasonable, these forward-looking statements are based on expectations, factors and assumptions about future events that could prove to be inaccurate and involve numerous risks and factors Subject to uncertainties, some of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s annual bulletin, which is available on Khiron’s SEDAR profile at www.sedar.com is available. The forward-looking information contained in this press release is expressly limited by this precaution and is current as of the date of this press release. Khiron makes no intention of and undertakes no obligation to update or revise any forward-looking information unless required by law, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
Contact for investors:
E: firstname.lastname@example.org T: +1 (647) 556-5750
Inquiries & contact:
Europe Communications Manager
Photo – mma.prnewswire.com/media/1482701/Khiron_Life_Sciences_Corp__Khiron_Expands_Product_Offering_in_UK.jpg
Photo – mma.prnewswire.com/media/1482702/Khiron_Life_Sciences_Corp__Khiron_Expands_Product_Offering_in_UK.jpg
Logo – mma.prnewswire.com/media/1482700/Khiron_Life_Sciences_Corp__Khiron_Expands_Product_Offering_in_UK.jpg